Harvard Bioscience (HBIO) Raw Materials (2011 - 2026)

Harvard Bioscience (HBIO) has reported Raw Materials for 16 consecutive years, with $13.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Raw Materials fell 10.47% year-over-year to $13.2 million in Q2 2026; TTM through Jun 2026 was $13.2 million, a 10.47% decrease from a year earlier, with the FY2025 full-year figure at $12.2 million, down 20.28% from the prior year.
• Raw Materials was $13.2 million for Q2 2026 at Harvard Bioscience, down from $13.3 million in the prior quarter.
• Over five years, Raw Materials peaked at $19.2 million in Q2 2022 and troughed at $12.2 million in Q4 2025.
• A 5-year average of $15.7 million and a median of $15.4 million in 2023 frame the typical range for Raw Materials.
• Across the five-year window, Raw Materials jumped 31.79% in 2022 and declined 24.1% in 2025, its largest moves.
• Over 5 years, Raw Materials stood at $17.4 million in 2022, then declined by 11.65% to $15.4 million in 2023, then decreased by 0.9% to $15.3 million in 2024, then declined by 20.28% to $12.2 million in 2025, then advanced by 8.59% to $13.2 million in 2026.
• The last three Raw Materials figures came in at $13.2 million (Q2 2026), $13.3 million (Q1 2026), and $12.2 million (Q4 2025), per Business Quant data.